News

News 2017-11-19T23:06:00+00:00

Pharmaxis releases positive results of Phase 1 clinical trial for LOXL2 inhibitor compound

LONDON, 11 October 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, today announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed [...]

October 11th, 2018|

Update on LogicBio proposed initial public offering in the United States

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 10 October 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that LogicBio Therapeutics Inc.(“LogicBio”) has filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering [...]

October 10th, 2018|

Co-leads $58 million Series A investment round for VelosBio

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014   Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio[1] to 15 companies Arix commits $11 million (£8.4 million)[2] for 11.2% ownership stake Co-investment with strategic partner Takeda and leading venture capital investors Arix further strengthens position in oncology; investment in VelosBio [...]

October 1st, 2018|

LogicBio files registration for proposed IPO in the US

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 26 September 2018: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, announces that one of its Group Businesses, LogicBio Therapeutics Inc. (“LogicBio”), a genome editing company focused on developing medicines to durably treat rare diseases in patients [...]

September 26th, 2018|

Update on Iterum Therapeutics Phase 3 trials

LONDON, 18 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Iterum Therapeutics plc (“Iterum”) (Nasdaq: ITRM) has initiated the remaining two of three planned Phase 3 pivotal trials (SURE 2 and SURE 3) of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections. Iterum [...]

September 18th, 2018|

ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 12 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announced that industry veteran Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors. Arix also announces, David U’Prichard is retiring from the Board, effective immediately. [...]

September 13th, 2018|

Changes announced to executive team to accelerate growth and strategy

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 4 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces planned changes to its executive team to prepare for its next phase of growth and development. Dr Joe Anderson, who has served as Chief Executive Officer of Arix [...]

September 4th, 2018|

Arix Bioscience announces first VIPE investment

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014  Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company advances numerous candidates from its Amine Oxidase drug discovery platform First Venture Investment in Public Equity (VIPE) led by Arix, taking core portfolio to 14 companies [...]

August 6th, 2018|

Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2018 LONDON, 30 July, 2018: Arix Bioscience plc (“Arix”, LSE: ARIX) a global healthcare and life science company supporting medical innovation, today announces its interim results for the period ended 30 June 2018. Financial highlights ▪ £35.6m net [...]

July 30th, 2018|

Autolus announces closing of IPO

LONDON, 26 June 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its largest Group Business holding Autolus Therapeutics plc (“Autolus”) has today announced the closing of its previously announced initial public offering (“IPO”) in the United States of 10,147,059 American Depositary Shares ("ADSs"), representing 10,147,059 ordinary shares, at an initial public offering price of $17.00 [...]

June 26th, 2018|